Replimune Group, Inc. $REPL Shares Purchased by SummitTX Capital L.P.

SummitTX Capital L.P. raised its stake in Replimune Group, Inc. (NASDAQ:REPL) by 165.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 288,889 shares of the company’s stock after purchasing an additional 180,086 shares during the period. SummitTX Capital L.P.’s holdings in Replimune Group were worth $2,210,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REPL. Walleye Capital LLC lifted its position in shares of Replimune Group by 3.2% during the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after buying an additional 2,192 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Replimune Group by 1.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock valued at $8,719,000 after buying an additional 20,742 shares during the last quarter. Candriam S.C.A. purchased a new position in shares of Replimune Group in the 1st quarter valued at $3,014,000. Y Intercept Hong Kong Ltd acquired a new stake in Replimune Group during the 1st quarter worth $528,000. Finally, SG Americas Securities LLC raised its stake in Replimune Group by 110.8% during the 1st quarter. SG Americas Securities LLC now owns 151,674 shares of the company’s stock worth $1,160,000 after acquiring an additional 79,719 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $5.35 on Wednesday. The company has a 50-day simple moving average of $9.35 and a 200-day simple moving average of $7.39. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $12.50. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. The stock has a market capitalization of $449.08 million, a price-to-earnings ratio of -1.58 and a beta of 0.86.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, analysts predict that Replimune Group, Inc. will post -2.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on REPL shares. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target for the company in a research report on Tuesday, June 30th. Jefferies Financial Group reiterated a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Wedbush boosted their target price on Replimune Group from $6.00 to $9.00 and gave the company a “neutral” rating in a report on Tuesday, June 30th. Weiss Ratings raised Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Finally, Cantor Fitzgerald cut Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.86.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.